Healthcare
There is almost always exciting research going on every day. Here are just a few that caught BioSpace’s attention this week.
The retail price of prescription drugs is a concern for many people in the United States. Now CVS is attempting to disrupt the retail end of things with a new savings finder tool.
Another major healthcare buyout may be on the horizon. According to reports, Walmart may be in talks to buy health insurer Humana.
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing cancer radiation therapy.
Shanghai’s C-Bridge Capital plans to raise $650M for its third healthcare PE fund, just six months after closing its second fund with $400M.
The 55-to-43 vote for Azar ushers in his return to the government’s largest domestic agency, where he held senior roles previously.
The 2016 U.S. presidential election was marked by aggressive and often shrill attacks on the biopharma industry over drug pricing.
Nestle submitted the highest offer and Merck was likely to select a winner during the first quarter, but might also choose not to sell the assets after all.
Shares of Agile plunged more than 62 percent in early trading after the company announced this morning the FDA rejected its low-dose hormonal contraceptive patch called Twirla.
Both Amazon and Rite Aid offered no comment for this story.
PRESS RELEASES